Cargando…

Residual Risk Still Remains in Low-Density Lipoprotein

Detalles Bibliográficos
Autor principal:	Hirano, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529400/ https://www.ncbi.nlm.nih.gov/pubmed/34955466 http://dx.doi.org/10.5551/jat.ED187

Ejemplares similares

Personalized Medicine beyond Low-Density Lipoprotein Cholesterol to Combat Residual Risk for Coronary Artery Disease
por: Tada, Hayato
Publicado: (2021)

The influence of triglycerides on small dense low‐density lipoprotein cholesterol levels is attenuated in low low‐density lipoprotein‐cholesterol range: Implications for the negative results of the PROMINENT trial
por: Hirano, Tsutomu, et al.
Publicado: (2023)

An Intriguing and Important Concept Relevant to Oxidized Low-Density Lipoprotein and Atherogenesis is Still Problematic for its Contribution to the Better Understanding of Clinical Atherosclerosis
por: Yoshida, Hiroshi
Publicado: (2018)

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol
por: Lawler, Patrick R., et al.
Publicado: (2017)

Lipoprotein(a) Removal Still a Mystery
por: Nestel, Paul
Publicado: (2019)

No change in small low‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
por: Hirano, Tsutomu
Publicado: (2023)

Of statins and low-density lipoprotein cholesterol, “fats” and fiction
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2016)

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes
por: Hayashi, Toshiyuki, et al.
Publicado: (2023)

Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
por: Lawler, Patrick R., et al.
Publicado: (2017)

Low‐density lipoprotein cholesterol and stroke: How low should we go?
por: Lui, David TW, et al.
Publicado: (2020)

Accuracy of Small Dense Low-density Lipoprotein-cholesterol Concentration Estimated via Sampson’s Equation in Healthy Subjects and Patients with Diabetes
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Beyond LDL: Understanding Triglyceride-Rich Lipoproteins to Tackle Residual Risk
por: Gugliucci, Alejandro
Publicado: (2023)

Knowledge Gap Regarding Low Density Lipoprotein-Cholesterol Levels in Koreans
por: Kim, Hyeon Chang
Publicado: (2012)

Current Status of Low-Density Lipoprotein Cholesterol and Cardiovascular Diseases in Japan
por: Sun, Wanlu, et al.
Publicado: (2023)

Lipoprotein(a): the enemy that we still don’t know how to defeat
por: Banach, Maciej
Publicado: (2023)

The diagnosis of primary hyperparathyroidism in developing countries remains in the past century: still with bones, stone and groans
por: Lazaretti-Castro, Marise
Publicado: (2020)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Is Non-High-Density Lipoprotein Cholesterol Evaluation Perfect? From the High-Density Lipoprotein Function Viewpoint
por: Otsuka, Toshiaki
Publicado: (2022)

Possible Regulation of Platelets by Native and Modified Low Density Lipoprotein-Cholesterol Particles
por: Han, Ki Hoon
Publicado: (2012)

Weight Gain After Smoking Cessation and Atherosclerotic Low-Density Lipoprotein Marker
por: Iida, Mami
Publicado: (2016)

Low Density Lipoprotein Cholesterol Target Goal Attainment Rate in Korean Patients with Diabetes
por: Lee, Eun Hae, et al.
Publicado: (2011)

Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?
por: Sabouret, Pierre, et al.
Publicado: (2022)

Lipoprotein (a)—We Know So Much Yet Still Have Much to Learn …
por: Banach, Maciej
Publicado: (2016)

High-Density Lipoproteins in Non-Cardiovascular Diseases
por: Zanotti, Ilaria
Publicado: (2022)

Re‐examining the high‐density lipoprotein hypothesis
por: Tan, Kathryn
Publicado: (2016)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Warning Against Low-Density Lipoprotein Oxidation in Users of Oral Combined Contraceptives
por: Bertolami, Marcelo Chiara
Publicado: (2018)

Risks of cancer in the Rohingya community of Bangladesh: An issue still remains unaddressed
por: Jubayer, Fahad, et al.
Publicado: (2020)

Low High-Density Lipoprotein and Risk of Myocardial Infarction
por: Ramirez, A., et al.
Publicado: (2015)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

To be Functional, or not to be Low in Cholesterol, that is the Clinical Concern when Evaluating Anti-Atherosclerotic Actions of High-Density Lipoproteins
por: Yoshida, Hiroshi
Publicado: (2021)

Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
por: Kim, Ji Yoon, et al.
Publicado: (2023)

There is light at the end of the tunnel, but we are still in the tunnel: universal preoperative SARS-CoV-2 testing and precautions remain vital in paediatrics
por: Adler, Adam C., et al.
Publicado: (2021)

Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein
Publicado: (1982)

Small-Dense Low-Density Lipoprotein Cholesterol: A Subclinical Marker for the Primary Prevention of Coronary Heart Disease
por: Kokubo, Yoshihiro, et al.
Publicado: (2020)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
por: Androulakis, Emmanuel, et al.
Publicado: (2017)

High-density lipoprotein: does it have a dark side?
por: Von Feldt, Joan M
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_679bjtuvobgm93m97aterrufc4